Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Poziotinib
Другие языки:

    Poziotinib

    Подписчиков: 0, рейтинг: 0
    Poziotinib
    Poziotinib.png
    Legal status
    Legal status
    • experimental
    Identifiers
    • 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C23H21Cl2FN4O3
    Molar mass 491.34 g·mol−1
    3D model (JSmol)
    • COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C
    • InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)
    • Key:LPFWVDIFUFFKJU-UHFFFAOYSA-N

    Poziotinib (NOV120101, HM781-36B) is a drug in development by Hanmi Pharmaceutical (in South Korea), Luye Pharma (China), and Spectrum Pharmaceuticals (rest of world) for various cancers.

    It is built on an anilino-quinazoline scaffold and inhibits the epidermal growth factor receptors EGFR, HER2/neu, and Her 4 and binds covalently to its targets.

    It was discovered at Hanmi; in August 2014 Hanmi exclusively licensed rights in China to the Chinese company Luye Pharma and in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum.

    As of 2016 Spectrum had started a Phase II trial of poziotinib a second-line treatment for breast cancer.


    Новое сообщение